Stocks
Funds
Screener
Sectors
Watchlists

Latest SR ONE CAPITAL MANAGEMENT, LP Stock Portfolio

SR ONE CAPITAL MANAGEMENT, LP Performance:
2025 Q3: 11.91%YTD: 7.79%2024: 15.52%

Performance for 2025 Q3 is 11.91%, and YTD is 7.79%, and 2024 is 15.52%.

About SR ONE CAPITAL MANAGEMENT, LP and 13F Hedge Fund Stock Holdings

In it's latest 13F Holdings report, SR One Capital Management, LP reported an equity portfolio of $691.4 Millions as of 30 Sep, 2025.

The top stock holdings of SR One Capital Management, LP are ACLX, CRSP, . The fund has invested 27.9% of it's portfolio in ARCELLX, INC. and 19.1% of portfolio in CRISPR THERAPEUTICS AG.

The fund managers got completely rid off KALA BIO, INC. (KALA) stocks. They significantly reduced their stock positions in MINERALYS THERAPEUTICS INC.. The fund showed a lot of confidence in some stocks as they added substantially to CRISPR THERAPEUTICS AG (CRSP).

SR ONE CAPITAL MANAGEMENT, LP Annual Return Estimates Vs S&P 500

Our best estimate is that SR One Capital Management, LP made a return of 11.91% in the last quarter. In trailing 12 months, it's portfolio return was -1.03%.

New Buys

No new stocks were added by SR ONE CAPITAL MANAGEMENT, LP

Additions

Ticker% Inc.
crispr therapeutics ag94.36

Additions to existing portfolio by SR ONE CAPITAL MANAGEMENT, LP

Reductions

Ticker% Reduced
mineralys therapeutics inc.-32.42

SR ONE CAPITAL MANAGEMENT, LP reduced stake in above stock

Sold off

Ticker$ Sold
kala bio, inc.-2,850,950

SR ONE CAPITAL MANAGEMENT, LP got rid off the above stocks

Sector Distribution

SR One Capital Management, LP has about 62.9% of it's holdings in Healthcare sector.

Sector%
Healthcare62.9
Others31.3
5.8

Market Cap. Distribution

SR One Capital Management, LP has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.

Category%
MID-CAP47
UNALLOCATED31.3
SMALL-CAP14.7
MICRO-CAP7.1

Stocks belong to which Index?

About 43.8% of the stocks held by SR One Capital Management, LP either belong to S&P 500 or RUSSELL 2000 index.

Index%
Others56.2
RUSSELL 200043.8
Top 5 Winners (%)%
DSGN
design therapeutics, inc.
123.4 %
NKTX
nkarta, inc.
24.7 %
ACLX
arcellx, inc.
24.7 %
ORIC
oric pharmaceuticals, inc.
18.2 %
CRSP
crispr therapeutics ag
14.7 %
Top 5 Winners ($)$
ACLX
arcellx, inc.
38.1 M
DSGN
design therapeutics, inc.
27.2 M
CRSP
crispr therapeutics ag
17.0 M
ORIC
oric pharmaceuticals, inc.
8.4 M
NKTX
nkarta, inc.
1.4 M
Top 5 Losers (%)%
SBTX
ars pharmaceuticals, inc.
-42.4 %
Top 5 Losers ($)$
SBTX
ars pharmaceuticals, inc.
-29.7 M

SR ONE CAPITAL MANAGEMENT, LP Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of SR ONE CAPITAL MANAGEMENT, LP

SR One Capital Management, LP has 12 stocks in it's portfolio. SBTX proved to be the most loss making stock for the portfolio. ACLX was the most profitable stock for SR One Capital Management, LP last quarter.

Last Reported on: 12 Nov, 2025
TickerNamesorted ascending% PortfolioShares Held$ ValueType% ChangeOptions